HALOZYME THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
HALOZYME THERAPEUTICS, INC. (HALO) had Debt Securities, Available-for-sale, Unrealized Loss Position of $8.90 million as of 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-05-11
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $8.90M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $9.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $63.00M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $280.80M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-03-31 | $8.90M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $9.00M 10-K · filed 2026-02-17 |
| 2025-09-30 | $63.00M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $280.80M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $340.90M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $250.30M 10-K · filed 2025-02-18 |
| 2024-09-30 | $74.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $315.50M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $215.50M 10-Q · filed 2024-05-07 |
| 2023-09-30 | $196.80M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $98.70M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $96.20M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $118.40M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $118.40M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $442.00M 10-Q · filed 2022-05-10 |
| 2021-09-30 | $66.00M 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |